Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony-Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy-Reference-Cited by-同舟云学术

Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony-Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy

Published:2004-04 Issue:4 Volume:24 Page:488-494
ISSN:0277-0008
Container-title:Pharmacotherapy
language:en
Short-container-title:Pharmacotherapy

Author:

Cosler Leon E.,Calhoun Elizabeth A.,Agboola Olayemi,Lyman Gary H.

Publisher

Wiley

Subject

Pharmacology (medical)

Reference17 articles.

1. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines

2. New Trends in Patient Management: Risk-Based Therapy for Febrile Patients with Neutropenia

3. Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

4. Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer

5. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study;Cancer Management and Research;2021-03

2. The evolution of value with filgrastim in oncology;Future Oncology;2019-05

3. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review;Critical Reviews in Oncology/Hematology;2015-05

4. G‐CSF utilization rate and prescribing patterns in United States : associations between physician and patient factors and GCSF use;Cancer Medicine;2014-11-20

5. Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review;Applied Health Economics and Health Policy;2013-10-16